DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) released its earnings results on Monday. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.01), Zacks reports.

DelMar Pharmaceuticals (NASDAQ DMPI) traded down $0.03 during midday trading on Tuesday, reaching $0.81. The company had a trading volume of 534,300 shares, compared to its average volume of 377,704. DelMar Pharmaceuticals has a twelve month low of $0.78 and a twelve month high of $5.39.

COPYRIGHT VIOLATION WARNING: This piece was reported by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at

Several research firms have recently weighed in on DMPI. Maxim Group cut DelMar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 14th. Dawson James reiterated a “buy” rating on shares of DelMar Pharmaceuticals in a report on Tuesday, August 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of DelMar Pharmaceuticals in a report on Thursday, October 5th.

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Earnings History for DelMar Pharmaceuticals (NASDAQ:DMPI)

Receive News & Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.